Antiplatelet Therapy in Chronic Urticaria

Chulalongkorn University

Status and phase: Active, not recruiting; Phase 2

Conditions: Chronic Urticaria

Treatments: Drug: Desloratadine; Drug: Desloratadine plus cilostazol and dipyridamole

Study type: Interventional

Funder types: Other

Identifiers

NCT06268470

Chula-ARC 001/18

Details and patient eligibility

About

This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria

Full description

This study is a randomized control trial comparing the effectiveness of the combination of antiplatelets and antihistamine and antihistamine alone for the treatment of chronic spontaneous urticaria

Enrollment: 12 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Chronic spontaneous urticaria

D-dimer levels over 500 ng/ml

Not respond to a conventional dose of antihistamine

Exclusion criteria

Are taking aspirin

Have bleeding tendency

Have concurrent severe medical illnesses

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

12 participants in 2 patient groups

Desloratadine

Active Comparator group

Description:

Oral desloratadine 20 mg/day (antihistamine) for 4 weeks

Treatment:

Drug: Desloratadine

Desloratadine plus cilostazol and dipyridamole

Experimental group

Description:

Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks

Treatment:

Drug: Desloratadine plus cilostazol and dipyridamole

Drug: Desloratadine